Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated…

By H. Burris, H. Hurwitz, E. Dees, A. Dowlati, K. Blackwell, B. O'Neil, P. Marcom, M. Ellis, B. Overmoyer, S. Jones and 6 more. Journal of Clinical Oncology, 2005

634 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/99b7b4f139af11bd903491f32d1cf9d7c20ac784